Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MICHAEL ANDREEFF and BING Z CARTER.
MICHAEL ANDREEFF
Connection Strength
16.039
BING Z CARTER
  1. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
    View in: PubMed
    Score: 0.919
  2. Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica. 2023 09 01; 108(9):2513-2519.
    View in: PubMed
    Score: 0.915
  3. Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 May 17; 13(1):80.
    View in: PubMed
    Score: 0.897
  4. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 04 24; 13(1):57.
    View in: PubMed
    Score: 0.893
  5. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Mol Cancer Ther. 2022 06 01; 21(6):879-889.
    View in: PubMed
    Score: 0.839
  6. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022 01 01; 107(1):58-76.
    View in: PubMed
    Score: 0.816
  7. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. Blood. 2021 10 28; 138(17):1637-1641.
    View in: PubMed
    Score: 0.806
  8. Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica. 2020 05; 105(5):1274-1284.
    View in: PubMed
    Score: 0.690
  9. An ARC-Regulated IL1?/Cox-2/PGE2/?-Catenin/ARC Circuit Controls Leukemia-Microenvironment Interactions and Confers Drug Resistance in AML. Cancer Res. 2019 03 15; 79(6):1165-1177.
    View in: PubMed
    Score: 0.665
  10. Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther. 2017 06; 16(6):1133-1144.
    View in: PubMed
    Score: 0.584
  11. Eradication of CML stem cells. Oncoscience. 2016; 3(11-12):313-315.
    View in: PubMed
    Score: 0.572
  12. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016 09 07; 8(355):355ra117.
    View in: PubMed
    Score: 0.564
  13. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget. 2016 Apr 12; 7(15):20054-67.
    View in: PubMed
    Score: 0.549
  14. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99.
    View in: PubMed
    Score: 0.530
  15. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014 Feb; 106(2):djt440.
    View in: PubMed
    Score: 0.471
  16. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis. 2011 Jan; 16(1):67-74.
    View in: PubMed
    Score: 0.380
  17. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol. 2010 Oct; 47(4):362-70.
    View in: PubMed
    Score: 0.374
  18. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood. 2010 Jan 14; 115(2):306-14.
    View in: PubMed
    Score: 0.351
  19. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008 Apr 01; 111(7):3742-50.
    View in: PubMed
    Score: 0.310
  20. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006 Oct; 5(19):2223-9.
    View in: PubMed
    Score: 0.283
  21. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15; 108(2):630-7.
    View in: PubMed
    Score: 0.273
  22. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood. 2006 Feb 15; 107(4):1555-63.
    View in: PubMed
    Score: 0.266
  23. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023 12; 9(48):eadh1436.
    View in: PubMed
    Score: 0.233
  24. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle. 2003 Sep-Oct; 2(5):488-93.
    View in: PubMed
    Score: 0.229
  25. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003 Dec 01; 102(12):4179-86.
    View in: PubMed
    Score: 0.228
  26. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Transl Oncol. 2022 Apr; 18:101354.
    View in: PubMed
    Score: 0.205
  27. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. Mol Cancer Ther. 2020 08; 19(8):1636-1648.
    View in: PubMed
    Score: 0.182
  28. Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res. 2018 05 15; 24(10):2417-2429.
    View in: PubMed
    Score: 0.156
  29. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016 Jun; 13(2):248-59.
    View in: PubMed
    Score: 0.138
  30. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia. Br J Haematol. 2014 Nov; 167(3):376-84.
    View in: PubMed
    Score: 0.122
  31. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014 May; 73(5):961-74.
    View in: PubMed
    Score: 0.119
  32. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9.
    View in: PubMed
    Score: 0.112
  33. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80.
    View in: PubMed
    Score: 0.105
  34. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood. 2011 Jan 20; 117(3):780-7.
    View in: PubMed
    Score: 0.094
  35. Apoptosis in leukemias: regulation and therapeutic targeting. Cancer Treat Res. 2010; 145:197-217.
    View in: PubMed
    Score: 0.089
  36. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther. 2009 Sep; 8(9):2509-16.
    View in: PubMed
    Score: 0.087
  37. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol. 2009 Oct 01; 27(28):4741-6.
    View in: PubMed
    Score: 0.086
  38. Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin. Leuk Lymphoma. 2007 Apr; 48(4):774-85.
    View in: PubMed
    Score: 0.073
  39. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005 May 15; 105(10):4043-50.
    View in: PubMed
    Score: 0.063
  40. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084.
    View in: PubMed
    Score: 0.061
  41. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma. 2024 Oct; 65(10):1511-1515.
    View in: PubMed
    Score: 0.060
  42. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
    View in: PubMed
    Score: 0.060
  43. Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia. 2024 Apr; 38(4):926.
    View in: PubMed
    Score: 0.060
  44. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia. 2024 Apr; 38(4):729-740.
    View in: PubMed
    Score: 0.058
  45. ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. Nat Commun. 2023 09 19; 14(1):5709.
    View in: PubMed
    Score: 0.057
  46. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discov. 2023 07 07; 13(7):1656-1677.
    View in: PubMed
    Score: 0.057
  47. Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia. Cells. 2023 04 11; 12(8).
    View in: PubMed
    Score: 0.056
  48. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
    View in: PubMed
    Score: 0.052
  49. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood. 2002 May 01; 99(9):3461-4.
    View in: PubMed
    Score: 0.052
  50. Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway. Clin Lymphoma Myeloma Leuk. 2022 09; 22(9):652-658.
    View in: PubMed
    Score: 0.052
  51. Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc Natl Acad Sci U S A. 2021 03 16; 118(11).
    View in: PubMed
    Score: 0.048
  52. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 11 26; 3(22):3661-3673.
    View in: PubMed
    Score: 0.044
  53. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):852-9.
    View in: PubMed
    Score: 0.018
  54. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood. 2007 Mar 01; 109(5):2121-9.
    View in: PubMed
    Score: 0.018
  55. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 2006 Aug 02; 98(15):1068-77.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.